ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Regorafenib modulates glucose metabolism, insulin/GLP-1 signaling, and tau pathology in an STZ-induced model of Alzheimer's disease.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeAlzheimer's disease (AD), often described as "type 3 diabetes" due to its metabolic and neuroendocrine features, is marked by impaired glucose metabolism and insulin signaling. This study aimed to investigate whether regorafenib, a multi-kinase inhibitor, could modulate glucose metabolism, insulin/glucagon-like peptide-1 (GLP-1) pathways, and tau pathology in a streptozotocin (STZ)-induced rat model of AD.
methodsMale rats (n = 5-8/group) received intracerebroventricular STZ to induce AD-like pathology and were subsequently treated with regorafenib for two weeks. Cognitive function was assessed using the Y-maze and novel object recognition (NOR) tests. Glucose metabolism was evaluated via 18F-FDG micro-PET imaging and glucose tolerance tests. Serum and hippocampal markers of insulin, GLP-1, and tau phosphorylation were measured.
resultsRegorafenib-treated rats exhibited significant improvement in recognition memory in the NOR test, while enhancement in spatial working memory in the Y-maze did not reach statistical significance. Regorafenib improved glucose metabolism in both the brain and periphery, as demonstrated by imaging and tolerance testing. Treatment significantly increased serum insulin and GLP-1 levels, and reduced hippocampal hyperphosphorylated tau, although hippocampal gene expression of insulin and GLP-1 signaling pathways remained unchanged.
conclusionRegorafenib may provide neuroprotective benefits in AD by improving glucose metabolism and reducing tau pathology. These findings suggest regorafenib as a potential novel therapeutic strategy for AD, though further research is needed to confirm its efficacy, assess long-term outcomes, and elucidate underlying mechanisms.
Indexed as
Identifiers
41003702What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.